A technique for dual determination of cytotoxic and helper lymphocyte precursor frequency by a miniaturized dye release method

Bone Marrow Transplantation

Volumn 23, Issue 1, 1999, Pages 71-78

  Hensel, N ^a   Agarwala, V ^a   Jiang, Y Z ^a   Mavroudis, D ^a   Molldrem, J ^a   Barrett, A J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Bone marrow transplantation; Calcein AM; CTLP; Histocompatibility testing; HTLP; Lymphocyte; Precursor frequency assays

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FLUORESCENT DYE; INTERLEUKIN 2;

ADOPTIVE TRANSFER; ARTICLE; BONE MARROW TRANSPLANTATION; CYTOTOXIC LYMPHOCYTE; DILUTION; FLUORESCENCE; HELPER CELL; HISTOCOMPATIBILITY TEST; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; NORMAL HUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROLYMPHOCYTE; SUPERNATANT;

EID: 0033006493     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701528     Document Type: Article

References (23)

1. Ryser JE, MacDonald HR. Limiting dilution analysis of alloantigen-reactive T lymphocytes. I. Comparison of precursor frequencies for proliferative and cytolytic responses. J Immunol 1979; 122: 1691-1696.
2. Sharrock CEM, Kaminski E, Man S. Limiting dilution analysis of human T cells: a useful clinical tool. Immunol Today 1990; 11: 281-286.
3. Kaminski E, Hows J, Man S et al. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation 1989; 48: 608-613.
4. Schwarer AP, Jiang YZ, Brookes PA et al. Frequency of antirecipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 1993; 341: 203-205.
5. Bouma GJ, Schanz U, Oudshoorn M et al. A cell-saving non-radioactive limiting dilution analysis-assay for the combined determination of helper and cytotoxic T lymphocyte precursor frequencies. Bone Marrow Transplant 1996; 17: 19-23.
6. Kaminski E, Sharrock C, Hows J et al. Frequency analysis of cytotoxic T lymphocyte precursors - possible relevance to HLA-mismatched unrelated donor bone marrow transplantation. Bone Marrow Transplant 1988; 3: 149-165.
7. Batchelor JR, Brookes PA, Davey NJ et al. In vitro methods and selection of HLA-matched unrelated donors for bone marrow transplantation. Transplantation Proc 1991; 23: 1711-1712.
8. Kaminski ER, Hows JM, Bridge J et al. Cytoloxic T lymphocyte precursor (CTL-p) frequency analysis in unrelated donor bone marrow transplantation: two case studies. Bone Marrow Transplant 1991; 8: 47-50.
9. Schwarer AP, Jiang YZ, Deacock S et al. Comparison of helper and cytotoxic antirecipient T cell frequencies in unrelated bone marrow transplantation. Transplantation 1994; 58: 1198-1203.
10. Speiser DE, Löluger C-C, Siren M-K et al. Pretransplant cytotoxic donor T-cell activity specific to patient HLA class I antigens correlating with mortality after unrelated BMT. Br J Haematol 1996; 93: 935-939.
11. 3H thymidine-based limiting dilution analysis to determine HTLp and CTLp frequencies for bone marrow donor selection. Bone Marrow Transplant 1997; 20: 149-155.
12. Wang XN, Proctor SJ, Dickinson AM. Frequency analysis of recipient-reactive helper and cytotoxic T lymphocyte precursors using a combined single limiting dilution assay. Transplant Immunol 1996; 4: 247-251.
13. Shih CC-Y, Truitt RL, Abramoff P et al. Relationship between IL-2 receptors and cyclosporine-induced suppression of T leukemia and helper cells. Transplantation Proc 1983; 15 (Suppl. 1): 2394-2397.
14. Deacock S, Schwarer A, Batchelor R et al. A rapid limiting dilution assay for measuring frequencies of alloreactive, interleukin-2-producing T cells in humans. J Immunol Meth 1992; 147: 83-92.
15. Wang XM, Terasaki PI, Rankin GW Jr et al. A new microcellular cytotoxicity test based on Calcein-AM release. Hum Immunol 1993; 37: 264-270.
16. Lewalle P, Hensel N, Guimaraes A et al. Helper and cytotoxic lymphocyte responses to chronic myeloid leukaemia: implications for adoptive immunotherapy with T cells. Br J Haematol 1996; 92: 587-594.
17. Kabelitz D, Herzog W-R, Heej K et al. Human cytotoxic T lymphocytes. III. Large numbers of peripheral blood T cells clonally develop into allorestricted anti-viral cytotoxic T cell populations in vitro. J Mol Cell Immunol 1987; 3: 49-60.
18. Man S, Lechler RI, Batchelor JR et al. Individual variation in the frequency of HLA class II-specific cytotoxic T lymphocyte precursors. Eur J Immunol 1990; 20: 847-854.
19. Cullis JO, Jiang YZ, Schwarer AP et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379-1381.
20. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
21. Lucas KG, Small TN, Heller G et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996; 87: 2594-2603.
22. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257: 238-241.
23. Molldrem J, Dermime S, Parker K et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450-2457.